Newsroom | 41533 results

Sorted by: Latest

Medical Devices
-

AdaptHealth Corp. to Participate in Upcoming Investor Conferences

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the following upcoming investor conferences: The Canaccord Genuity 46th Annual Growth Conference, being held in Boston, on Tuesday, August 11, 2026, including a fireside chat from 9:00 – 9:25 a.m. E...
-

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o...
-

Aegis Sciences Names Joel Galanter Interim CEO

NASHVILLE, Tenn.--(BUSINESS WIRE)--Aegis Sciences Corporation (“Aegis” or the “Company”) today announced it has named Joel Galanter Interim CEO, replacing Frank Basile who served as the company’s CEO since 2017. With more than a decade in senior executive leadership at Aegis, Galanter brings deep institutional knowledge and broad experience across the Company's operations, regulatory environment, and strategic priorities. Galanter has directly overseen the Company's legal, regulatory, governmen...
-

Inogen Announces Second Quarter 2026 Financial Results

BEVERLY, Mass.--(BUSINESS WIRE)--Reported second quarter revenue of $95.1 million. Company raises full-year adjusted EBITDA guidance to approximately $4.0 million...
-

TriSalus Life Sciences Reports Second Quarter 2026 Results

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our f...
-

Hyperfine, Inc. Reports Second Quarter 2026 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2026 financial results and provided a business update. “Q2 was another strong quarter for Hyperfine, marked by solid growth in placements and revenue, continued gross margin expansion, disciplined operating expense...
-

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.) Gross margin of 57%, up 460 basis points compared to second quarter 2025 Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in t...
-

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences....
-

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approxim...
-

ForSight Robotics Demonstrates Fully Robotic-Assisted Cataract Surgery Within the Standard Clinical Workflow of the World's Most Commonly Performed Surgical Procedure

CAESAREA, Israel--(BUSINESS WIRE)--ForSight Robotics, a global pioneer in robotic eye surgery, today announced a significant milestone in the clinical evolution of ophthalmic robotics, demonstrating that fully robotic-assisted cataract surgery can be successfully integrated into the standard clinical workflow of the world's most commonly performed surgical procedure. Building on the Company's historic first-in-human achievement announced earlier this year, ForSight Robotics has successfully com...